Topic: Medicare Part D

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • After 4 Years of Trump, Medicare and Medicaid Badly Need Attention

  • Modeling P-quad

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

  • Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

    Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

  • List Price, Net Price, and the Rebate Caught in the Middle

  • Association of Rebates in Part D with Patient OOP and Federal Spending

    Association of Rebates in Part D with Patient OOP and Federal Spending